Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease

Fujita, K.; Nozaki, Y.; Wada, K.; Yoneda, M.; Endo, H.; Takahashi, H.; Iwasaki, I.; Inamori, M.; Abe, Y.; Kobayashi, N.; Kirikoshi, H.; Kubota, K.; Saito, S.; Nagashima, Y.; Nakajima, A.
November 2008
Gut;Nov2008, Vol. 57 Issue 11, p1583
Academic Journal
Objective: No effective drugs have been developed to date to prevent or treat non-alcoholic fatty liver disease (NAFLD), although diet modification and exercise to improve obesity have been attempted. Therefore, development of a novel drug/strategy to treat NAFLD is urgently needed. In the present study, a novel concept is proposed for the treatment of NAFLD. Methods: Fisher 344 male rats were given a cholinedeficient, L-amino acid-defined (CDAA) diet or a high-fat high-calorie (HF/HC) diet with or without the antiplatelet agents, aspirin, ticlopidine or cilostazol for 16 weeks. Liver steatosis, inflammation and fibrosis, and the possible mechanisms involved were investigated. Results: All three antiplatelet drugs, namely aspirin, ticlopidine and cilostazol, significantly attenuated liver steatosis, inflammation and fibrosis in the CDAA diet group. Of the three agents, cilostazol was the most effective, and the drug also suppressed HF/HC dietinduced liver steatosis. Cilostazol appeared to exert its beneficial effect against NAFLO by suppressing mitogenactivated protein kinase activation induced by oxidative stress and platelet-derived growth factor via intercepting signal transduction from Akt to c-Raf. Conclusion: Antiplatelet agents, especially cilostazol, offer the promise of becoming key agents for the treatment of NAFLD.


Related Articles

  • The Effects of Rosiglitazone, Metformin, and Diet with Exercise in Nonalcoholic Fatty Liver Disease. Kadir Demir; Sadakat Özdil; Nevzat Aksoy; Şule Poturoğlu; Duygu Ä°brişim; Sabahattin Kaymakoğlu; Fatih Beşışık; Güngör Boztaş; Yılmaz Çakaloğlu; Zeynel Mungan; Uğur Çevikbaş; Atilla Ökten // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2359 

    Abstract  Our aım was to evaluate effects of metformin, rosiglitazone, and diet with exercise in nonalcoholic fatty liver disease. Forty-seven patients (mean age, 44�10 years; 17 female) whose ALT levels had been high for at least 6 months and with...

  • Nonalcoholic Fatty Liver Disease and Reduced Serum Vitamin D3 Levels. Targher, Giovanni; Scorletti, Eleonora; Mantovani, Alessandro; Byrne, Christopher D. // Metabolic Syndrome & Related Disorders;Aug2013, Vol. 11 Issue 4, p217 

    Nonalcoholic fatty liver disease (NAFLD) and vitamin D3 deficiency are two highly prevalent pathologic conditions worldwide that share several cardiometabolic risk factors. In addition to its traditional calcium-related effects on the skeleton, vitamin D3 deficiency has now been recognized to...

  • NON-ALCOHOLIC FATTY LIVER DISEASE—WHAT IS CURRENT UK PRACTICE? Campbell, E.; Mohammed, I.; Elias, E. // Gut;Apr2003 Supplement 1, Vol. 52, pA102 

    Background: Non-alcoholic fatty liver disease (NAFLD) encompasses steatosis and steatohepatitis. The prevalence of NAFLD is increasing but it is unclear how clinicians are managing this condition. This study aimed to establish how NAFLD is diagnosed and managed within the UK. Methods: A postal...

  • Studying non-alcoholic fatty liver disease with zebrafish: a confluence of optics, genetics, and physiology. Schlegel, Amnon // Cellular & Molecular Life Sciences;Dec2012, Vol. 69 Issue 23, p3953 

    Obesity is a public health crisis. New methods for amelioration of its consequences are required because it is very unlikely that the social and economic factors driving it will be reversed. The pathological accumulation of neutral lipids in the liver (hepatic steatosis) is an obesity-related...

  • Exercise and the fatty liver. Spassiani, Natasha A.; Kuk, Jennifer L. // Applied Physiology, Nutrition & Metabolism;Aug2008, Vol. 33 Issue 4, p802 

    Fatty liver is an increasingly prevalent condition that is associated with several metabolic derangements, thus necessitating the development of effective therapeutic interventions. Growing evidence from cross-sectional studies suggest that physical activity may be a promising therapy for fatty...

  • Steatosis and Steatohepatitis: Complex Disorders. Bettermann, Kira; Hohensee, Tabea; Haybaeck, Johannes // International Journal of Molecular Sciences;Jun2014, Vol. 15 Issue 6, p9924 

    Non-alcoholic fatty liver disease (NAFLD) which includes steatosis and steatohepatitis, in particular non-alcoholic steatohepatitis (NASH), is a rising health problem world-wide and should be separated from alcoholic steatohepatitis (ASH). NAFLD is regarded as hepatic manifestation of the...

  • Nonalcoholic Fatty Liver Disease. Angulo, Paul // New England Journal of Medicine;4/18/2002, Vol. 346 Issue 16, p1221 

    Presents information on nonalcoholic fatty liver disease. Description of the disease; Symptoms, including obesity and type 2 diabetes mellitus; Prevalence of the disease; Way that the disease manifests itself; How the disease is diagnosed.

  • Non-alcoholic fatty liver disease in Japanese patients.  // Clinical Cardiology Alert;Apr2010 Primary Care Supplement, Vol. 15 Issue 4, p8 

    The article discusses research on the histological course of nonalcoholic fatty liver disease in Japanese patients, which references a study by E. Hamaguchi and colleagues published in a 2010 issue of "Diabetes Care."

  • Fatty Liver in a Case with Heterozygous Familial Hypobetalipoproteinemia. Ogata, Hisanobu; Akagi, Kimihiro; Baba, Mitsuo; Nagamatsu, Akio; Suzuki, Norihisa; Nomiyama, Kensuke; Fujishima, Masatoshi // American Journal of Gastroenterology;Feb1997, Vol. 92 Issue 2, p339 

    We herein present a case of fatty liver in a patient with heterozygous familial hypobetalipoproteinemia. A 34-yr-old male presented with abnormally elevated levels of transaminases and a fatty liver. He was asymptomatic, and the physical examination showed nothing remarkable. The serum total...


Read the Article


Sign out of this library

Other Topics